1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC
(2022) ESMO Congress 2022 — Location: (France) Paris (9.September.2022)
Files
2022_Auclin_ESMO2022.pdf
Open Access - Adobe PDF
- 110.25 KB
Details
- Authors
- Abstract
- BACKGROUND : In first line (L1) for EGFR-mutated (mEGFR) advanced NSCLC (aNSCLC), osimertinib (osi) has been the preferred option since 2018. First generation anti-EGFR TKI (1G) alone followed by osi, or 1G + anti-angiogenic or 1G + chemotherapy are other options. We aimed to assess the subgroups of patients (pts) that do not benefit from 1G alone compared with osimertinib L1 in mEGFR aNSCLC. [...]
- Affiliations
Citations
Auclin, E., Du Rusquec, P., Albarran, V., Aboubakar Nana, F., Gerber, H., Epaillard, N., Recondo, G., Berthou, H., Fabre-Guillevin, E., Laguna Montes, J. C., Blaquier, J. B., Jimenez Munarriz, B. E., Tagliamento, M., Sacco, G., Minatta, J. N., Girard, N., Moran Bueno, M. T., López Castro, R., Besse, B., & Mezquita, L. (2022). 1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC. Annals of Oncology, 33(Suppl 7), S1078. https://doi.org/10.1016/j.annonc.2022.07.1281 (Original work published 2022)